| Literature DB >> 26366342 |
Kunitaka Kuramoto1, Toru Beppu2, Tomohiro Namimoto3, Hiromitsu Hayashi1, Katsunori Imai1, Hidetoshi Nitta1, Daisuke Hashimoto1, Akira Chikamoto1, Takatoshi Ishiko1, Ken-Ichi Iyama4, Osamu Ikeda3, Yasuyuki Yamashita3, Hideo Baba1.
Abstract
BACKGROUND: Angiomyolipoma is a unique mesenchymal neoplasm composed of blood vessels as well as smooth muscle and adipose cells. The liver is a less common site of origin, and hepatic angiomyolipoma is often an incidental finding on diagnostic imaging or is identified on evaluation of nonspecific symptoms. CASEEntities:
Keywords: Apparent diffusion coefficient (ADC); Chemical shift imaging; Diffusion-weighted MRI; Early venous return; Hepatic angiomyolipoma
Year: 2015 PMID: 26366342 PMCID: PMC4560139 DOI: 10.1186/s40792-015-0038-0
Source DB: PubMed Journal: Surg Case Rep ISSN: 2198-7793
Clinical characteristics of the patients
|
|
|
|---|---|
| Gender (male/female) | 3/1 |
| Age (years) | 72, 54, 51, 59 |
| Symptom (positive/negative) | 1/3 |
| Diagnostic method (resection/biopsy) | 3/1 |
| HBs-Ag (positive/negative) | 1/3 |
| HCV-Ab (positive/negative) | 0/4 |
| Liver cirrhosis (positive/negative) | 0/4 |
| Child-Pugh (A/B) | 4/0 |
| Tumor diameter (mm) | 12, 20, 22, 100 |
| Number of tumor | All solitary |
| Tumor markers | |
| AFP (ng/ml) | 2.7, 3.4, 3.9, 11.5 |
| DCP (mAU/ml) | 13, 24, 25, 28 |
| CEA (ng/ml) | 0.6, 1.0,1.3, 2.5 |
| CA19-9 (U/ml) | 1.0, 2.5, 3.3, 4.5 |
HBs-Ag, hepatitis B surface antigen; HCV, anti-hepatitis C virus antibody; AFP, alpha-fetoprotein; DCP, des-gamma-carboxyl prothrombin; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9.
Diagnostic imaging of the patients
|
|
|
|---|---|
| US - a heterogeneously hyperechoic mass (yes/no) | 3/1 |
| CT | |
| Plain CT - a heterogeneously low density mass with low attenuation value (< −20 HU) (yes/no) | 2/2 |
| Contrast-enhanced CT - early enhancement with delayed washout (yes/no) | 3/1 |
| Not round margin, the tumor border was irregular without capsular formation (yes/no) | 1/3 |
| Intratumoral vessels (yes/no) | 2/2 |
| Homogeneous enhancement (yes/no) | 2/2 |
| MRI | |
| T1-weighted imaging (hypo/hyper/mixed) | 2/1/1 |
| T2-weighted imaging (hypo/hyper/mixed) | 0/1/3 |
| Fat component in chemical shift imaging (yes/no) | 3/1 |
| ADC in diffusion-weighted imaging | 0.91/1.21/1.80/3.66 |
| Hypointensity in hepatobiliary phase on T1-weighted imaging (Gd-EOB-DTPA) (yes/no) | 2/0 |
| Intratumoral vessels (yes/no) | 1/3 |
| Homogeneous enhancement (yes/no) | 2/2 |
| Dynamic CT, CT angiography, or MRI early venous return (yes/no) | 3/1 |
US, ultrasonography; CT, computed tomography; MRI, magnetic resonance imaging; ADC, apparent diffusion coefficient; Gd-EOB-DTPA, gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid.
Figure 1A case of Gd-EOB-DTPA-enhanced MRI findings of huge AML. In the T1W in-phase image (A), the tumor itself is mixed intense in hypointense surroundings. In the in-phase hyperintense signal areas (white arrow), the loose signal in the T1W out-of-phase image (B) is consistent with the fat content (F). In the arterial phase image (C), a minor part of the tumor was remarkably enhanced (arrow) and this part is consistent with meandering blood vessels (G). In DWI, (D) MRI displays an obvious hyperintense signal, whereas in the hepatobiliary phase (E), it shows a homogenous hypointense signal. Major parts of the tumor are consistent with the smooth muscle cell component/components (H), and these lesions were positive for HMB-45 and Melan-A.
Figure 2A case of AML with early venous return. CT angiography via the left hepatic artery showed a patchy enhanced tumor in S3 with early venous return to left hepatic vein (arrow).